New approaches to developing antidepressants by enhancing monoaminergic neurotransmission
Frank P. Bymaster, Robert K. McNamara, Pierre V. Trân · Expert Opinion on Investigational Drugs · 2003
Major depressive disorder (MDD) is a serious illness with far reaching societal and economic ramifications. The monoamine-deficiency hypothesis that depressive symptoms are associated with reductions in monoamine neurotransmission, particularly serotonin and noradrenaline, is supported by both neurochemical findings and the successful treatment of MDD with compounds that enhance monoaminergic neurotransmission. This review focuses on novel compounds in different stages of development for the treatment of MDD that enhance monoaminergic neurotransmission via a number of different mechanisms, including re-uptake inhibition of one or more monoamines, monoamine oxidase inhibitors, the combination of monoamine antagonists with re-uptake inhibitors and monoamine receptor subtype agonists. Compounds that enhance individual monoamines have antidepressant properties and compounds that enhance multiple monoamines appear to have a synergistic antidepressant effect and potentially faster onset of action. The differing mechanisms of action possessed by these novel monoamine-enhancing compounds will offer greater treatment flexibility in the therapeutic management of MDD.
Cited by 56 works. doi:10.1517/13543784.12.4.531
Authors
References
- Lifetime and 12-Month Prevalence of DSM-III-R Psychiatric Disorders in the United States
- The global burden of disease: a comprehensive assessment of mortality and disability from diseases injuries and risk factors in 1990 and projected to 2020.
- Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments
- Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus
- Clinical update on amisulpride in deficit schizophrenia
- Depression in the community
- Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors
- Pharmacological profile of antidepressants and related compounds at human monoamine transporters
- Atomoxetine in the Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: A Randomized, Placebo-Controlled, Dose-Response Study
- Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes